Table 1.
Baseline Characteristics of the Cohort by Treatment Assignment
| Pitavastatin (n = 25) | Placebo (n = 25) | |
|---|---|---|
| Demographics | ||
| Age, y | 52.8 ± 1.3 | 52.9 ± 1.4 |
| Race, n (%) | ||
| White | 24 (96) | 21 (84) |
| Nonwhite | 1 (4) | 3 (12) |
| Not reported | 0 | 1 (4) |
| Current smoker, n (%) | 4 (16) | 4 (16) |
| Antihypertensive use, n (%) | 9 (36) | 5 (20) |
| Lipid profile | ||
| Total cholesterol, mg/dL | 182 ± 4 | 196 ± 6a |
| LDL-C, mg/dL | 130 ± 4 | 137 ± 5 |
| HDL-C, mg/dL | 41 ± 1 | 42 ± 2 |
| Triglycerides, mg/dL | 132 ± 12 | 152 ± 14 |
| Metabolic parameters | ||
| SBP, mm Hg | 135 ± 3 | 136 ± 3 |
| DBP, mm Hg | 83 ± 2 | 80 ± 2 |
| Fasting glucose, mg/dLb | 91 ± 2 | 91 ± 1 |
| 2-h glucose OGTT, mg/dLb | 139 ± 6 | 131 ± 7 |
| HOMA-IRb | 2.7 ± 0.3 | 3.2 ± 0.3 |
| Creatinine, mg/dL | 0.81 ± 0.03 | 0.88 ± 0.02 |
Continuous data reported as mean ± SEM.
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
a
P = 0.05 (all other baseline comparisons between treatment groups P > 0.05).
b
Fasting glucose, 2-h glucose, and HOMA-IR as assessed at screening visit as part of eligibility criteria.